AlphAIAlphAI — Financial news for AI agents
quiverquant.comSEP 91 min read$VOGX

William Wilkison Net Worth (2026)

William Wilkison reportedly owns 1.8 million shares of Vanguard Extended Duration Treasury ETF (VOGX), valued at $56.6 million. No insider trades have been filed by Wilkison in VOGX since 2021, according to SEC filings.

Original reporting
quiverquant.com
Published Sep 9, 2026, 2:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
William Wilkison Net Worth (2026) — source image
Source · quiverquant.com
Decision brief

The 30-second read

$VOGXBullishMed
01

Why it matters

The disclosed ownership size is sizable relative to the company's market cap, indicating insider confidence.

02

Market read

New insider holding data provides fresh material for traders evaluating VOGX.

03

What to watch

No recent trades disclosed; the stake may have been built over time, limiting immediate impact.

Relevance 7/10Novelty 7/10Timing: recent filing

Background

Form 4 filings disclose insider transactions; VOGX is a listed security.

Company-level read

Ticker impact

$VOGXBullishHigh confidence
Context

SEC Form 4 shows insider William Wilkison now holds 1.8M shares (~$56.6M) after no recent trades.

Expected impact

Potential modest upside as market digests increased insider ownership.

Evidence & confidence

Form 4 is a primary disclosure; the size of the holding is material for a micro‑cap.

Market effects

Sector

Minimal; insider activity is specific to VOGX.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider accumulation could signal overvaluation; watch for future sell‑off.

Key entities

  • person
    William Wilkison

    Insider filing Form 4 for VOGX.

Read at source← All news

Related articles

OCT 15
$VOGXMed

Vogenx initiates phase 2b trial for post-bariatric hypoglycemia

Vogenx (NASDAQ:VOGX) began a Phase 2b trial for mizagliflozin to treat post-bariatric hypoglycemia. The EMERGE trial will enroll 36 adults with recurrent hypoglycemia post-surgery, testing 5 mg and 10 mg doses against placebo. Mizagliflozin is an investigational SGLT1 inhibitor, with no FDA-approved treatments currently available for this condition.

investing.com4 min
OCT 15
$VOGXMed

Blood-sugar drops after weight-loss surgery have no FDA-approved treatment. Vogenx starts a trial.

Vogenx (NASDAQ:VOGX) initiated a Phase 2b trial for mizagliflozin, a treatment for post-bariatric hypoglycemia (PBH), a condition with no FDA-approved therapies. The EMERGE trial will enroll 36 adults, testing 5 mg and 10 mg doses against placebo. Mizagliflozin aims to reduce hypoglycemic events by delaying glucose absorption in the small intestine. Vogenx's CEO and CSO highlighted the trial's significance and the drug's potential.

stocktitan.net4 min
AUG 28
$VOGXMed

Vogenx Inc - Common Stock (VOGX)

Vogenx, Inc. (VOGX) closed its initial public offering of 6.25 million shares at $13.00 per share, raising approximately $81.3 million before expenses. The biopharmaceutical company focuses on treatments for metabolic dysfunctions, including post-bariatric hypoglycemia and gastroparesis.

financialcontent.com1 min